Cagrilintide is a lipidated, long-acting analogue of the pancreatic hormone amylin, described by Kruse et al. (2021). It has been tested in clinical trials for obesity and type 2 diabetes, alone and combined with semaglutide (CagriSema), including the phase 3 REDEFINE programme.
KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP-NH2 (Cys2–Cys7 disulfide; acylated with a C20 fatty diacid via a γGlu linker; attachment site not confirmed in sources checked)
2021: Kruse T, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem 64(15) (PMID 34288673).
Regulatory status
Investigational and not approved in the US or EU. Novo Nordisk submitted an NDA to the FDA in December 2025 for CagriSema; a decision was expected in 2026, and no approval was found as of October 2026.
SHLabz batch results
No SHLabz batch of Cagrilintide has a published report yet. Each batch is tested by an independent laboratory, and the report for a batch is available on request through the contact page.
This sheet describes a molecule and the published research on it. It is not advice about use, and SHLabz products are not for human or veterinary use.
Trusted research supplier — UAE & GCC
The UAE & GCC’s Trusted Source for Lab‑Verified Research Peptides
Research-grade peptides at ≥99% purity, third-party HPLC tested and
released against a certificate of analysis. 1–2 working days across the UAE, 3–5 across the GCC.
≥99% purity, third-party HPLC tested and
released against a certificate of analysis. Dispatched the same working day.
